Konu "Nivolumab" için Scopus İndeksli Yayınlar Koleksiyonu listeleme
Toplam kayıt 3, listelenen: 1-3
-
Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience
(Springer, 2020)Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved ... -
Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience
(Oxford University Press, 2017)Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, ... -
Nivolumab-induced lichen planus
(SAGE Publications, 2020)Introduction:Renal cell carcinomas account for 90% of all malignant neoplasms of the kidney. The most common types of renal cancer in adults are clear cell and papillary renal cell carcinoma; sporadic cases of renal ...